# An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

> **NCT00001810** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 300 (—)

## Conditions studied

- Aspergillosis
- Candidiasis
- Fungemia
- Mycoses

## Interventions

- **DRUG:** Voriconazole

## Key facts

- **NCT ID:** NCT00001810
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-04
- **Primary completion:** —
- **Final completion:** 2000-10
- **Target enrollment:** 300 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001810, "An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00001810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*